Beranda › Tumor Neuroendokrin › Arizona
Uji klinis Tumor Neuroendokrin di Arizona
7 studi untuk Tumor Neuroendokrin mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Mayo Clinic Hospital, Phoenix
- The University of Arizona Cancer Center, Tucson
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06943755Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- Banner MD Anderson Cancer Center, Gilbert
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Phoenix
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- Kingman Regional Medical Center, Kingman
- Banner Children's at Desert, Mesa
- Phoenix Childrens Hospital, Phoenix
- dan 1 lainnya
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Phoenix
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Scottsdale Medical Imaging, LLC, Scottsdale
Menerima pesertaFase 4
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 22 Jan 2026 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.